摘要
目的:探讨了肺癌患者化疗前后血清IGF-Ⅱ、CEA和VEGF水平的变化及临床意义。方法:应用放射免疫分析和酶联法对33例肺癌患者进行了化疗前后血清IGF-Ⅱ、CEA和VEGF检测,并与35名正常健康人作比较。结果:肺癌患者在化疗前血清IGF-Ⅱ、CEA和VEGF水平均非常显著地高于正常人组(P<0.01),经化疗6个月后与正常人组比较仍有显著性差异(P<0.05)。结论:肺癌的发生、发展与血清IGF-Ⅱ、CEA和VEGF水平的变化密切相关。
in patients with lung cancer. Methods Serum IGF-Ⅱ ,CEA（with RIA） and serum VEGF（with ELISA） levels were determined both before and after chemotherapy in 33 patients with lung cancer as well as in 35 normal controls. Results Before chemotherapy, serum IGF- Ⅱ , CEA and VEGF levels were significantly higher in the patients than those in controls （ P 〈 0.01 ）. Six months after chemotherapy, serum IGF- Ⅱ, CEA and VEGF levels dropped markedly, but remained evidently higher than those in controls（ P 〈 0.05 ）. Con- clusion The development and progression of lung cancer in patients was closely related to the changes of serum IGF- Ⅱ, CEA and VEGF levels.
出处
《放射免疫学杂志》
CAS
2012年第2期140-142,共3页
Journal of Radioimmanology
关键词
肺癌胰岛素样生长因子-Ⅱ
癌胚抗原血管内皮生长因子
lung cancer, insulin-like growth factor-ll （IGF-I1 ）, carcinoembryonic antigen （CEA）, vascular endothelialgrowth factor （VEGF）
